WEBVTT

00:00:00.111 --> 00:00:02.412 align:center
Welcome to this webinar hosted by

00:00:02.432 --> 00:00:02.992 align:center
APTA-HEM.

00:00:04.153 --> 00:00:06.134 align:center
My name is Erika Medin and

00:00:06.234 --> 00:00:07.394 align:center
I will be the moderator of

00:00:07.434 --> 00:00:08.075 align:center
this event.

00:00:10.035 --> 00:00:11.296 align:center
I have worked with APTA-HEM for

00:00:11.376 --> 00:00:14.117 align:center
almost ten years supporting management with

00:00:14.217 --> 00:00:17.319 align:center
primarily communication and IR activities.

00:00:19.300 --> 00:00:20.760 align:center
The purpose of this webinar is

00:00:20.800 --> 00:00:23.381 align:center
to provide an overview of APTA-HEM's

00:00:23.581 --> 00:00:24.762 align:center
strategic direction

00:00:25.818 --> 00:00:27.879 align:center
ongoing preparations for a planned US

00:00:27.939 --> 00:00:30.820 align:center
listing, and recent key regulatory

00:00:31.400 --> 00:00:31.980 align:center
developments.

00:00:34.741 --> 00:00:36.022 align:center
Some practical information.

00:00:36.982 --> 00:00:39.643 align:center
CEO Mikael Lindstam will start by

00:00:39.683 --> 00:00:40.884 align:center
giving his presentation.

00:00:41.864 --> 00:00:43.705 align:center
After the presentation, we will answer

00:00:43.745 --> 00:00:45.265 align:center
the questions that you send us

00:00:45.305 --> 00:00:46.065 align:center
during the event.

00:00:47.386 --> 00:00:49.026 align:center
You can send your questions via

00:00:49.066 --> 00:00:51.367 align:center
questions and answers, which you find

00:00:51.427 --> 00:00:53.148 align:center
to the right on your screen.

00:00:54.543 --> 00:00:55.483 align:center
You will not be able to

00:00:55.543 --> 00:00:56.724 align:center
ask questions verbally.

00:00:58.084 --> 00:00:59.884 align:center
The webinar will be recorded and

00:00:59.964 --> 00:01:02.585 align:center
published on our websites and social

00:01:02.605 --> 00:01:03.325 align:center
media channels.

00:01:04.646 --> 00:01:06.026 align:center
With that, I hand over to

00:01:06.086 --> 00:01:06.946 align:center
you, Mikael.

00:01:07.806 --> 00:01:09.647 align:center
Thank you so much, Erika, and

00:01:09.707 --> 00:01:10.627 align:center
welcome, everyone.

00:01:10.647 --> 00:01:13.128 align:center
As Erika said, I'm Michael Lindström.

00:01:13.228 --> 00:01:14.848 align:center
I'm the CEO of Dahem, and

00:01:14.868 --> 00:01:16.969 align:center
I'm also co-founder of the company.

00:01:17.569 --> 00:01:19.169 align:center
Today, I'm going to talk about

00:01:19.289 --> 00:01:21.670 align:center
the horrors of sepsis and

00:01:22.421 --> 00:01:24.102 align:center
how we could approach making a

00:01:24.142 --> 00:01:25.463 align:center
better world for those who actually

00:01:25.503 --> 00:01:27.384 align:center
get struck by sepsis.

00:01:27.664 --> 00:01:29.366 align:center
And I also present a little

00:01:29.406 --> 00:01:31.847 align:center
about the company, the lead candidate

00:01:31.887 --> 00:01:33.908 align:center
that we have for our approach

00:01:34.009 --> 00:01:36.390 align:center
to curing, or at least making

00:01:36.450 --> 00:01:37.931 align:center
better for those who get sepsis,

00:01:38.291 --> 00:01:40.973 align:center
a little forward moving where we

00:01:40.993 --> 00:01:42.514 align:center
are going and what we have

00:01:42.534 --> 00:01:43.955 align:center
done also, a little backwards.

00:01:44.055 --> 00:01:47.017 align:center
But let's start with actually the

00:01:47.577 --> 00:01:48.218 align:center
big thing that,

00:01:50.180 --> 00:01:51.121 align:center
Did you switch, by the way,

00:01:51.501 --> 00:01:51.801 align:center
Rika?

00:01:52.602 --> 00:01:53.042 align:center
Or I did it.

00:01:55.403 --> 00:01:55.664 align:center
Okay.

00:01:56.144 --> 00:01:56.424 align:center
Okay.

00:01:56.464 --> 00:01:57.065 align:center
Sorry about that.

00:01:57.185 --> 00:01:57.505 align:center
Okay.

00:01:57.585 --> 00:01:57.985 align:center
Sepsis.

00:01:58.245 --> 00:01:59.186 align:center
I just spoke about that.

00:01:59.206 --> 00:02:02.328 align:center
Here is something that we should

00:02:02.368 --> 00:02:03.349 align:center
look very careful at.

00:02:03.529 --> 00:02:07.672 align:center
Fifty million people per year get

00:02:07.712 --> 00:02:08.112 align:center
sepsis.

00:02:09.593 --> 00:02:12.136 align:center
twenty percent of those die that

00:02:12.196 --> 00:02:14.157 align:center
is extreme and i will come

00:02:14.198 --> 00:02:15.699 align:center
back to this uh with further

00:02:15.719 --> 00:02:18.181 align:center
slides ahead of us but it's

00:02:18.281 --> 00:02:20.223 align:center
one of the most frequent cause

00:02:20.323 --> 00:02:21.625 align:center
of a death in the world

00:02:22.145 --> 00:02:23.687 align:center
and if we look here twenty

00:02:23.727 --> 00:02:25.288 align:center
twenty as i just mentioned twenty

00:02:25.368 --> 00:02:30.093 align:center
percent was uh hit by sepsis

00:02:30.213 --> 00:02:31.794 align:center
and died so that means

00:02:32.495 --> 00:02:33.976 align:center
Twenty percent of those fifty were

00:02:34.016 --> 00:02:35.277 align:center
hit by this.

00:02:35.297 --> 00:02:37.859 align:center
And sepsis is such a situation

00:02:37.899 --> 00:02:39.400 align:center
that there are no real direct

00:02:39.460 --> 00:02:39.761 align:center
cures.

00:02:39.781 --> 00:02:40.781 align:center
There are a lot of different

00:02:40.841 --> 00:02:43.203 align:center
remedies to treat those who get

00:02:43.223 --> 00:02:43.984 align:center
struck by sepsis.

00:02:44.024 --> 00:02:46.185 align:center
But it's also about the timing,

00:02:46.686 --> 00:02:50.068 align:center
luck and other things that you

00:02:50.108 --> 00:02:51.609 align:center
will soon see on the next

00:02:51.650 --> 00:02:52.950 align:center
slides coming up.

00:02:53.711 --> 00:02:55.232 align:center
And the problem is that it

00:02:55.392 --> 00:02:57.374 align:center
also put a big burden on

00:02:57.414 --> 00:03:00.196 align:center
society, socio-economic burden.

00:03:01.073 --> 00:03:02.294 align:center
You can lose a loved one,

00:03:02.655 --> 00:03:05.657 align:center
a working comrade, and also treatment.

00:03:06.197 --> 00:03:07.759 align:center
And the longevity, if you have

00:03:07.819 --> 00:03:11.041 align:center
the luck to survive, costs a

00:03:11.082 --> 00:03:11.582 align:center
lot of money.

00:03:11.642 --> 00:03:16.266 align:center
But in approximately around terms, US

00:03:17.527 --> 00:03:18.748 align:center
dollars for a treatment.

00:03:18.848 --> 00:03:20.249 align:center
It could be more depending on

00:03:20.269 --> 00:03:21.190 align:center
the hospitalization.

00:03:23.460 --> 00:03:24.561 align:center
And here we have a few

00:03:24.601 --> 00:03:25.381 align:center
scenarios.

00:03:25.641 --> 00:03:26.942 align:center
We call it the phase of

00:03:27.062 --> 00:03:27.522 align:center
sepsis.

00:03:28.062 --> 00:03:28.942 align:center
If you look to the far

00:03:29.162 --> 00:03:30.863 align:center
left, this is something that could

00:03:30.903 --> 00:03:31.223 align:center
happen.

00:03:31.543 --> 00:03:34.825 align:center
You have a really evil infection

00:03:35.045 --> 00:03:36.285 align:center
that goes septic.

00:03:36.625 --> 00:03:38.146 align:center
That means you start to see

00:03:39.387 --> 00:03:40.307 align:center
tissue breakdown.

00:03:40.387 --> 00:03:41.347 align:center
And that's what you see here

00:03:41.387 --> 00:03:42.048 align:center
to the left.

00:03:43.342 --> 00:03:45.203 align:center
And that's just the beginning.

00:03:45.583 --> 00:03:46.444 align:center
And if you then look at

00:03:46.464 --> 00:03:47.945 align:center
the mid picture, I will come

00:03:47.965 --> 00:03:49.346 align:center
back to that because it's actually

00:03:49.406 --> 00:03:50.787 align:center
video, which we will soon show

00:03:50.847 --> 00:03:52.688 align:center
you is the effect.

00:03:52.768 --> 00:03:55.970 align:center
If you are lucky, unlucky patient

00:03:55.990 --> 00:03:57.571 align:center
for sepsis, it can end up

00:03:57.611 --> 00:03:59.392 align:center
with with amputations.

00:04:01.433 --> 00:04:03.215 align:center
Or you die, or you manage

00:04:03.235 --> 00:04:04.095 align:center
to survive anyway.

00:04:04.375 --> 00:04:05.376 align:center
What you can see here in

00:04:05.396 --> 00:04:07.678 align:center
the picture of this young woman

00:04:07.718 --> 00:04:09.219 align:center
in the middle is that you

00:04:09.320 --> 00:04:11.761 align:center
can also have severe organ damage

00:04:12.122 --> 00:04:12.742 align:center
and other things.

00:04:13.103 --> 00:04:15.124 align:center
Mostly those lead to death, but

00:04:15.144 --> 00:04:17.466 align:center
you can also go through that

00:04:17.506 --> 00:04:19.047 align:center
without dying, but you have severe

00:04:19.208 --> 00:04:20.409 align:center
aftermath of such things.

00:04:21.089 --> 00:04:22.090 align:center
And then we have an example

00:04:22.130 --> 00:04:23.550 align:center
where you are lucky or you

00:04:23.590 --> 00:04:24.651 align:center
had good treatment.

00:04:24.691 --> 00:04:25.731 align:center
You come in a good time.

00:04:25.771 --> 00:04:27.432 align:center
And that is the well-known Madonna.

00:04:27.892 --> 00:04:29.493 align:center
She got struck by sepsis and

00:04:29.733 --> 00:04:30.833 align:center
she managed to pull through.

00:04:31.454 --> 00:04:33.935 align:center
So and, you know, eighty percent

00:04:33.955 --> 00:04:34.355 align:center
survive.

00:04:34.895 --> 00:04:36.776 align:center
But how many are actually surviving

00:04:36.816 --> 00:04:37.697 align:center
in the case of the mid

00:04:38.017 --> 00:04:38.477 align:center
part here?

00:04:38.917 --> 00:04:40.178 align:center
And I would like Rika to

00:04:40.258 --> 00:04:42.799 align:center
just show a short video on

00:04:42.839 --> 00:04:44.960 align:center
that young woman, what she's gone

00:04:44.980 --> 00:04:45.160 align:center
through.

00:04:48.893 --> 00:04:51.374 align:center
It wasn't obvious that I had

00:04:51.474 --> 00:04:53.736 align:center
something that life-threatening that was about

00:04:53.776 --> 00:04:54.236 align:center
to occur.

00:04:54.856 --> 00:04:55.817 align:center
I had what felt like a

00:04:55.937 --> 00:04:56.317 align:center
cold.

00:04:57.498 --> 00:04:58.739 align:center
I thought it was just general

00:04:58.799 --> 00:05:00.280 align:center
end of term kind of sickness.

00:05:00.700 --> 00:05:03.041 align:center
I do sometimes worry what could

00:05:03.061 --> 00:05:05.603 align:center
have happened had my housemate not

00:05:05.643 --> 00:05:06.804 align:center
seen that my light was still

00:05:06.864 --> 00:05:08.265 align:center
on and that I was awake

00:05:08.285 --> 00:05:09.866 align:center
in the middle of the night

00:05:10.506 --> 00:05:12.007 align:center
as when I did end up

00:05:12.087 --> 00:05:13.948 align:center
in any things took a turn

00:05:13.968 --> 00:05:15.329 align:center
for the worse quite rapidly.

00:05:20.494 --> 00:05:22.015 align:center
This is life for Lily now,

00:05:22.476 --> 00:05:24.618 align:center
learning how to complete simple tasks

00:05:24.698 --> 00:05:26.259 align:center
as a quadruple amputee.

00:05:27.220 --> 00:05:27.701 align:center
Thank you.

00:05:27.741 --> 00:05:28.542 align:center
We can go back to the

00:05:28.582 --> 00:05:29.482 align:center
presentation, please.

00:05:31.685 --> 00:05:32.525 align:center
Thank you, Rika.

00:05:33.226 --> 00:05:35.088 align:center
So here's an example, as I

00:05:35.108 --> 00:05:37.070 align:center
just mentioned, where you survive, but

00:05:37.130 --> 00:05:39.752 align:center
with a huge handicap to come

00:05:39.772 --> 00:05:40.373 align:center
from that one end.

00:05:40.990 --> 00:05:43.552 align:center
You know, this is no secret

00:05:43.672 --> 00:05:45.594 align:center
why they call it the silent

00:05:45.614 --> 00:05:45.874 align:center
death.

00:05:47.135 --> 00:05:47.976 align:center
Thank you so much.

00:05:50.298 --> 00:05:51.659 align:center
As I just was saying, it's

00:05:51.719 --> 00:05:53.320 align:center
no secret that you call it

00:05:53.340 --> 00:05:54.161 align:center
the silent death.

00:05:55.122 --> 00:05:56.523 align:center
I mean, as she mentioned here,

00:05:56.643 --> 00:05:57.884 align:center
she wasn't aware of what would

00:05:57.904 --> 00:05:58.224 align:center
happen.

00:05:58.264 --> 00:05:59.145 align:center
And it can take such an

00:05:59.205 --> 00:06:01.047 align:center
easy thing like poking your nose

00:06:01.387 --> 00:06:02.488 align:center
with a dirty finger and get

00:06:02.508 --> 00:06:03.569 align:center
the bacterial infection there.

00:06:04.349 --> 00:06:05.690 align:center
And that can lead to something

00:06:05.911 --> 00:06:07.152 align:center
like an infection of some sort.

00:06:07.172 --> 00:06:08.253 align:center
You get a little fever, this

00:06:08.313 --> 00:06:08.613 align:center
and that.

00:06:08.873 --> 00:06:09.854 align:center
And without

00:06:10.666 --> 00:06:11.747 align:center
Just out of the blue, you

00:06:11.787 --> 00:06:12.848 align:center
can be hit by a very

00:06:12.908 --> 00:06:14.951 align:center
severe infection response in your body

00:06:15.011 --> 00:06:16.132 align:center
if your immune system is not

00:06:16.172 --> 00:06:17.153 align:center
there to protect you.

00:06:17.673 --> 00:06:18.734 align:center
And that's what happened with her.

00:06:18.875 --> 00:06:20.036 align:center
And that happened to some other

00:06:20.076 --> 00:06:20.697 align:center
people as well.

00:06:21.297 --> 00:06:22.578 align:center
Hence all the deaths we have.

00:06:23.960 --> 00:06:26.122 align:center
So with that, let's go on

00:06:26.182 --> 00:06:27.904 align:center
to see why is sepsis not

00:06:27.944 --> 00:06:28.405 align:center
top ranked?

00:06:29.394 --> 00:06:31.056 align:center
Here we have World Health Organization

00:06:31.116 --> 00:06:35.442 align:center
again showing the ten biggest death

00:06:36.824 --> 00:06:38.086 align:center
reasons in the world.

00:06:38.566 --> 00:06:39.367 align:center
If you look to the left,

00:06:39.407 --> 00:06:40.669 align:center
you see that sixty eight million

00:06:40.689 --> 00:06:43.253 align:center
in twenty twenty one died.

00:06:43.273 --> 00:06:45.616 align:center
And that's, of course, probably added

00:06:45.696 --> 00:06:47.058 align:center
a little from the COVID situation.

00:06:47.723 --> 00:06:48.764 align:center
And here you see the ten

00:06:48.804 --> 00:06:51.546 align:center
top causes of death.

00:06:52.626 --> 00:06:53.647 align:center
And as you can see, they

00:06:53.747 --> 00:06:56.229 align:center
are relating to fifty seven percent

00:06:56.489 --> 00:06:57.049 align:center
of all deaths.

00:06:57.670 --> 00:07:00.732 align:center
So WHO says eleven million deaths

00:07:00.772 --> 00:07:01.172 align:center
per year.

00:07:01.692 --> 00:07:03.814 align:center
So putting that in the context

00:07:03.914 --> 00:07:05.455 align:center
of that ischemic heart disease, which

00:07:05.535 --> 00:07:07.717 align:center
is top, are nine million deaths

00:07:07.757 --> 00:07:08.077 align:center
per year.

00:07:09.017 --> 00:07:11.461 align:center
That gives some strange thinking, at

00:07:11.481 --> 00:07:12.803 align:center
least for us at Aptaheim and

00:07:12.823 --> 00:07:13.764 align:center
others too, I would guess.

00:07:13.784 --> 00:07:14.566 align:center
But I will come to that

00:07:14.586 --> 00:07:16.549 align:center
in the next slide and explaining

00:07:16.709 --> 00:07:18.752 align:center
how sepsis actually are hidden in

00:07:18.852 --> 00:07:20.535 align:center
many different sickness conditions.

00:07:22.452 --> 00:07:23.193 align:center
And here we have it.

00:07:23.473 --> 00:07:26.055 align:center
You recognize the list or the

00:07:26.335 --> 00:07:27.557 align:center
ten biggest as we had in

00:07:27.597 --> 00:07:28.257 align:center
previous slide.

00:07:28.998 --> 00:07:30.919 align:center
And here you can see how

00:07:31.040 --> 00:07:34.002 align:center
these are relating to sepsis or

00:07:34.322 --> 00:07:35.163 align:center
can give sepsis.

00:07:36.564 --> 00:07:37.705 align:center
And as you see here, there's

00:07:37.745 --> 00:07:38.306 align:center
different reasons.

00:07:38.346 --> 00:07:39.567 align:center
I will not go through everything,

00:07:39.627 --> 00:07:39.787 align:center
but

00:07:41.062 --> 00:07:42.602 align:center
There are always a situation with

00:07:42.622 --> 00:07:44.223 align:center
these conditions that may lead to

00:07:44.263 --> 00:07:46.624 align:center
sepsis, as you can see from

00:07:46.764 --> 00:07:47.464 align:center
this different.

00:07:47.764 --> 00:07:49.265 align:center
And if I just take a

00:07:49.325 --> 00:07:51.625 align:center
few examples, if you look in

00:07:51.645 --> 00:07:54.186 align:center
the middle, this with oxygen imbalance

00:07:54.226 --> 00:07:55.406 align:center
when it comes to ischemic heart

00:07:55.446 --> 00:07:57.027 align:center
disease leading to inflammatory response.

00:07:57.967 --> 00:07:59.888 align:center
Body reacts very bad if it

00:07:59.928 --> 00:08:01.048 align:center
doesn't have oxygen enough.

00:08:01.308 --> 00:08:03.449 align:center
That means it can start to

00:08:03.949 --> 00:08:04.809 align:center
damage the tissue.

00:08:04.829 --> 00:08:06.990 align:center
The tissue is dissolved.

00:08:08.177 --> 00:08:10.398 align:center
And because you need oxygen to

00:08:10.458 --> 00:08:12.459 align:center
keep your tissue as well as

00:08:12.499 --> 00:08:14.781 align:center
your organs in good condition.

00:08:14.921 --> 00:08:15.781 align:center
And this is where it all

00:08:15.801 --> 00:08:16.241 align:center
can start.

00:08:17.562 --> 00:08:19.143 align:center
Of course, there are certain reasons,

00:08:19.203 --> 00:08:20.544 align:center
and pneumonia is a very common

00:08:20.584 --> 00:08:20.884 align:center
reason.

00:08:20.944 --> 00:08:24.766 align:center
It's a bacterial pneumonia, for example,

00:08:25.986 --> 00:08:29.468 align:center
that also leads to deficiency in

00:08:29.548 --> 00:08:32.050 align:center
oxygen uptake, which leads then to

00:08:32.070 --> 00:08:32.770 align:center
a tissue

00:08:33.426 --> 00:08:35.508 align:center
breakdown and that goes into a

00:08:35.528 --> 00:08:37.049 align:center
spiral where you have tougher and

00:08:37.069 --> 00:08:38.250 align:center
tougher to breathe and that could

00:08:38.290 --> 00:08:42.713 align:center
also extend into a septic condition.

00:08:42.873 --> 00:08:44.715 align:center
So there's many different reasons here

00:08:44.755 --> 00:08:46.536 align:center
when it comes to sensitive organs

00:08:46.996 --> 00:08:49.358 align:center
like the lungs, the only open

00:08:49.438 --> 00:08:51.139 align:center
organ in our bodies, but also

00:08:51.219 --> 00:08:53.341 align:center
kidneys were extremely sensitive.

00:08:53.381 --> 00:08:54.182 align:center
And as I mentioned at the

00:08:54.202 --> 00:08:54.582 align:center
beginning,

00:08:55.824 --> 00:08:57.605 align:center
I will bring this forward to

00:08:57.705 --> 00:08:58.926 align:center
where we are going with the

00:08:59.006 --> 00:09:01.247 align:center
company for the next study.

00:09:01.327 --> 00:09:03.288 align:center
That means patient studies phase two.

00:09:03.669 --> 00:09:04.529 align:center
I will come back to that

00:09:04.569 --> 00:09:05.630 align:center
a few slides down.

00:09:06.210 --> 00:09:09.552 align:center
But there's many reasons from this

00:09:09.632 --> 00:09:11.293 align:center
top ten that can lead to

00:09:11.333 --> 00:09:12.254 align:center
a safety condition.

00:09:12.594 --> 00:09:14.915 align:center
And that is also something not

00:09:14.955 --> 00:09:16.516 align:center
many people know, but we should

00:09:16.536 --> 00:09:17.417 align:center
be aware about that.

00:09:19.518 --> 00:09:20.678 align:center
And what do we have in

00:09:20.779 --> 00:09:23.300 align:center
APTA one in APTA-HEM?

00:09:24.160 --> 00:09:25.141 align:center
It's our lead candidate.

00:09:26.045 --> 00:09:27.906 align:center
And it's an RNA aptamer.

00:09:28.066 --> 00:09:29.906 align:center
An aptamer is an oligo.

00:09:30.126 --> 00:09:32.527 align:center
And an oligo is something that

00:09:32.767 --> 00:09:34.188 align:center
is coming more and more in

00:09:34.348 --> 00:09:35.728 align:center
our surrounding world when it comes

00:09:35.788 --> 00:09:36.428 align:center
to treatments.

00:09:37.549 --> 00:09:39.650 align:center
You have heard about AOCs perhaps,

00:09:39.970 --> 00:09:40.870 align:center
and there's the O in the

00:09:40.970 --> 00:09:41.450 align:center
oligos.

00:09:41.850 --> 00:09:43.251 align:center
So oligos getting more and more

00:09:43.431 --> 00:09:46.912 align:center
traction into the medical, the therapeutic

00:09:46.952 --> 00:09:47.372 align:center
industry.

00:09:47.952 --> 00:09:49.853 align:center
So, but back to APTA-I.

00:09:50.493 --> 00:09:52.974 align:center
We have a novel mechanism.

00:09:53.034 --> 00:09:53.734 align:center
And what does it mean?

00:09:54.595 --> 00:09:55.575 align:center
Because APTA-I,

00:09:56.412 --> 00:09:58.273 align:center
goes in to our target protein

00:09:58.313 --> 00:10:00.854 align:center
in this case from bin it

00:10:00.954 --> 00:10:02.894 align:center
binds on from bin which is

00:10:03.255 --> 00:10:06.436 align:center
the driving force mechanism or protein

00:10:06.896 --> 00:10:10.417 align:center
that signaling at an adverse effect

00:10:10.477 --> 00:10:11.878 align:center
with an inflammatory response in the

00:10:11.898 --> 00:10:13.898 align:center
body so that is massively fallout

00:10:14.379 --> 00:10:15.859 align:center
and here we can dock on

00:10:15.919 --> 00:10:17.720 align:center
with APTA one to a very

00:10:17.760 --> 00:10:20.081 align:center
specific point called exercise two or

00:10:20.101 --> 00:10:22.602 align:center
the heparin binding motif which is

00:10:22.642 --> 00:10:23.182 align:center
also called

00:10:23.942 --> 00:10:26.264 align:center
And what's so special with APTA-one

00:10:26.304 --> 00:10:27.805 align:center
when it binds to thrombin is

00:10:27.825 --> 00:10:29.186 align:center
that it only binds to one

00:10:29.326 --> 00:10:31.307 align:center
point, only one place, and that's

00:10:31.347 --> 00:10:32.048 align:center
the exercise two.

00:10:32.748 --> 00:10:34.549 align:center
Other drugs out there may bind

00:10:34.569 --> 00:10:36.891 align:center
to other places on thrombin, and

00:10:36.931 --> 00:10:38.772 align:center
those usually lead to side effects.

00:10:38.812 --> 00:10:40.313 align:center
And the most common side effect,

00:10:40.614 --> 00:10:42.355 align:center
which is other drugs, which usually

00:10:42.475 --> 00:10:44.416 align:center
could be an anticoagulant, leads to

00:10:45.497 --> 00:10:46.618 align:center
a bleeding side effect.

00:10:47.358 --> 00:10:48.700 align:center
Because we don't bind to these

00:10:48.860 --> 00:10:51.523 align:center
other sites, we avoid having these

00:10:51.563 --> 00:10:53.165 align:center
side effects because we keep the

00:10:53.225 --> 00:10:56.650 align:center
blood system, the homeostasis, at a

00:10:56.730 --> 00:10:58.312 align:center
very good level.

00:10:58.792 --> 00:11:01.115 align:center
It doesn't get imbalanced, which happens

00:11:01.296 --> 00:11:02.557 align:center
at the septic condition.

00:11:04.043 --> 00:11:07.125 align:center
and also downstream from thrombin we

00:11:07.245 --> 00:11:09.887 align:center
affect signal and also called the

00:11:09.947 --> 00:11:12.849 align:center
platelet activation and there we have

00:11:12.889 --> 00:11:15.570 align:center
the key to stop the inflammatory

00:11:15.590 --> 00:11:17.292 align:center
response in the body especially when

00:11:17.492 --> 00:11:19.093 align:center
in sepsis you have this what

00:11:19.133 --> 00:11:20.393 align:center
we call cytokine storm it's a

00:11:20.614 --> 00:11:23.816 align:center
total rolling inflammatory response and body

00:11:23.876 --> 00:11:25.457 align:center
cannot really respond to that the

00:11:26.057 --> 00:11:27.838 align:center
own immune system doesn't know really

00:11:27.878 --> 00:11:29.399 align:center
what to do and get confused

00:11:29.439 --> 00:11:30.340 align:center
and then it rolls over

00:11:31.061 --> 00:11:33.445 align:center
So that's what we see we

00:11:33.485 --> 00:11:35.789 align:center
could actually put a hampering to

00:11:36.230 --> 00:11:36.971 align:center
and also regulate.

00:11:36.991 --> 00:11:37.953 align:center
But we'll come back to that

00:11:38.013 --> 00:11:38.334 align:center
later.

00:11:40.117 --> 00:11:42.602 align:center
So that's about APTA one, our

00:11:42.622 --> 00:11:43.303 align:center
lead candidate.

00:11:44.283 --> 00:11:45.563 align:center
So we have done a lot

00:11:45.623 --> 00:11:47.244 align:center
of investigations without that one.

00:11:47.304 --> 00:11:48.844 align:center
First, we did the preclinic studies

00:11:49.164 --> 00:11:50.945 align:center
and we did loads of preclinic

00:11:51.005 --> 00:11:51.385 align:center
studies.

00:11:52.085 --> 00:11:53.765 align:center
Being a new kind of modality

00:11:54.005 --> 00:11:56.006 align:center
and also doing things that no

00:11:56.066 --> 00:11:58.246 align:center
one's seen before had us do

00:11:58.366 --> 00:11:59.947 align:center
a lot of preclinic studies.

00:12:00.327 --> 00:12:02.307 align:center
And there was comparative studies, there

00:12:02.367 --> 00:12:05.508 align:center
were different models, there were also

00:12:05.668 --> 00:12:06.868 align:center
a lot of benchmarking.

00:12:07.048 --> 00:12:08.729 align:center
I already mentioned something.

00:12:09.229 --> 00:12:11.130 align:center
that I will bring forward further

00:12:11.751 --> 00:12:12.491 align:center
down the line here.

00:12:12.911 --> 00:12:13.872 align:center
But if we look at this,

00:12:13.912 --> 00:12:15.233 align:center
we've done a lot of sepsis

00:12:15.293 --> 00:12:17.874 align:center
models or sepsis-like models, and we

00:12:17.934 --> 00:12:19.335 align:center
could see how we could improve

00:12:19.355 --> 00:12:21.677 align:center
survival enormously at some settings.

00:12:22.307 --> 00:12:23.668 align:center
and we can dampen the inflammatory

00:12:23.708 --> 00:12:26.489 align:center
response, we could counterbalance the

00:12:26.809 --> 00:12:27.369 align:center
coagulation

00:12:27.409 --> 00:12:29.610 align:center
system and homeostasis, we could also

00:12:29.770 --> 00:12:32.291 align:center
stimulate the body's own immune system

00:12:32.551 --> 00:12:33.351 align:center
to get it up to a

00:12:33.431 --> 00:12:35.572 align:center
level, actually above the levels what

00:12:35.592 --> 00:12:37.333 align:center
we would see it could do

00:12:37.413 --> 00:12:39.433 align:center
by itself without the stimulation of

00:12:39.473 --> 00:12:40.694 align:center
Atala, which is fantastic.

00:12:41.574 --> 00:12:42.295 align:center
And if you look to the

00:12:42.335 --> 00:12:43.655 align:center
left here, you see we have

00:12:43.675 --> 00:12:46.197 align:center
done something called RDS studies.

00:12:46.297 --> 00:12:49.899 align:center
And RDS is acute respiratory distress

00:12:49.939 --> 00:12:50.259 align:center
syndrome.

00:12:50.839 --> 00:12:51.940 align:center
It happens when you have a

00:12:51.980 --> 00:12:53.641 align:center
very severe lung infection of some

00:12:53.701 --> 00:12:53.981 align:center
sort.

00:12:54.562 --> 00:12:55.682 align:center
In this case, it was not

00:12:55.722 --> 00:12:56.623 align:center
bacteria we worked with.

00:12:56.663 --> 00:12:58.124 align:center
We worked with a viral.

00:12:58.244 --> 00:12:59.424 align:center
That means we have introduced the

00:12:59.465 --> 00:12:59.765 align:center
virus.

00:12:59.785 --> 00:13:00.745 align:center
And we could see how we

00:13:00.845 --> 00:13:05.088 align:center
could improve the situation for those

00:13:05.108 --> 00:13:06.108 align:center
who got APTA-one.

00:13:06.469 --> 00:13:07.889 align:center
In this case, we have a

00:13:07.989 --> 00:13:08.770 align:center
maintained viral.

00:13:09.430 --> 00:13:11.032 align:center
or healthier lung tissue.

00:13:11.712 --> 00:13:12.833 align:center
And one of the most important

00:13:12.853 --> 00:13:14.334 align:center
things, and I mentioned it before,

00:13:14.855 --> 00:13:16.456 align:center
is that we could maintain a

00:13:16.516 --> 00:13:19.378 align:center
good oxygen pressure or oxygen delivery

00:13:19.498 --> 00:13:21.180 align:center
to the tissue.

00:13:21.300 --> 00:13:23.041 align:center
And that is key in this

00:13:23.161 --> 00:13:23.442 align:center
case.

00:13:24.142 --> 00:13:26.584 align:center
And just to mention something is

00:13:26.644 --> 00:13:29.366 align:center
that within the care today in

00:13:29.426 --> 00:13:31.848 align:center
sepsis, they make sure to try

00:13:31.908 --> 00:13:33.730 align:center
to maintain a good blood pressure,

00:13:33.750 --> 00:13:35.451 align:center
which is not always, of course,

00:13:36.032 --> 00:13:38.313 align:center
possible when all your vascular leaking

00:13:38.434 --> 00:13:39.955 align:center
because of the tissues breaking down.

00:13:40.075 --> 00:13:41.636 align:center
But we can stay with that.

00:13:42.076 --> 00:13:43.037 align:center
We could see that we could

00:13:43.057 --> 00:13:44.218 align:center
maintain a good blood pressure.

00:13:44.238 --> 00:13:45.639 align:center
Now we've seen in all our

00:13:45.679 --> 00:13:47.221 align:center
studies that we have been maintaining

00:13:47.261 --> 00:13:48.482 align:center
in these study models

00:13:49.362 --> 00:13:51.904 align:center
And again, key to keep healthy

00:13:51.964 --> 00:13:53.845 align:center
tissue or healthy organs.

00:13:54.825 --> 00:13:56.586 align:center
We did these thrombosis models where

00:13:56.626 --> 00:13:59.588 align:center
we compared to different anticoagulants out

00:13:59.608 --> 00:14:01.249 align:center
there or antithrombotic agents.

00:14:02.049 --> 00:14:04.490 align:center
And what was significant for these

00:14:04.510 --> 00:14:06.271 align:center
studies, all kind of different ones,

00:14:06.311 --> 00:14:07.352 align:center
and I will show you on

00:14:07.372 --> 00:14:09.513 align:center
the slide further down, is that

00:14:10.194 --> 00:14:12.195 align:center
in comparison or benchmark testing, we

00:14:12.235 --> 00:14:13.415 align:center
could see that we do not

00:14:13.455 --> 00:14:14.676 align:center
have this bleeding side effect.

00:14:14.896 --> 00:14:16.037 align:center
And we also have a very

00:14:16.077 --> 00:14:17.758 align:center
pronounced antithrombotic effect.

00:14:17.798 --> 00:14:18.098 align:center
That means

00:14:18.798 --> 00:14:20.159 align:center
If it's over clotting a system

00:14:20.179 --> 00:14:21.159 align:center
that could lead to a stop

00:14:21.199 --> 00:14:23.080 align:center
in the vascular, we could reduce

00:14:23.120 --> 00:14:23.360 align:center
those.

00:14:23.560 --> 00:14:26.461 align:center
We could also stop further clotting.

00:14:26.521 --> 00:14:28.822 align:center
So both reducing the thrombosis and

00:14:29.022 --> 00:14:29.582 align:center
also

00:14:32.423 --> 00:14:33.463 align:center
reducing and stopping them.

00:14:33.843 --> 00:14:35.704 align:center
So that's quite a very strong

00:14:35.724 --> 00:14:38.125 align:center
feature without the common side effect.

00:14:38.825 --> 00:14:39.785 align:center
So if you go over to

00:14:39.805 --> 00:14:41.306 align:center
the right side, we also did

00:14:41.326 --> 00:14:42.786 align:center
a first in man study, which

00:14:42.806 --> 00:14:43.907 align:center
we call the phase one study.

00:14:44.407 --> 00:14:45.987 align:center
And that was done with our

00:14:46.027 --> 00:14:47.368 align:center
Dutch collaborators.

00:14:48.510 --> 00:14:50.672 align:center
And that felt very good out

00:14:50.713 --> 00:14:51.994 align:center
of safety and we could see

00:14:52.034 --> 00:14:52.935 align:center
no side effects there.

00:14:53.755 --> 00:14:55.177 align:center
And during that study, a very

00:14:55.197 --> 00:14:56.798 align:center
specific thing happened that one of

00:14:56.818 --> 00:14:58.860 align:center
the healthy volunteers actually came in

00:14:58.920 --> 00:15:01.383 align:center
and had a moderate viral infection.

00:15:02.223 --> 00:15:03.525 align:center
And that's not

00:15:04.185 --> 00:15:06.746 align:center
supposed to be a healthy individual.

00:15:06.766 --> 00:15:08.447 align:center
But in this case, this person

00:15:08.467 --> 00:15:08.907 align:center
slipped through.

00:15:09.428 --> 00:15:11.149 align:center
Anyway, the positive thing here is

00:15:11.189 --> 00:15:12.949 align:center
that we could see APTA-one have

00:15:13.029 --> 00:15:15.391 align:center
an effect within eight hours doing

00:15:15.471 --> 00:15:17.132 align:center
exactly what we have seen in

00:15:17.192 --> 00:15:20.373 align:center
our other models beforehand and doing

00:15:20.393 --> 00:15:22.214 align:center
preclinical studies, which was a very

00:15:22.254 --> 00:15:23.235 align:center
good and

00:15:25.135 --> 00:15:26.517 align:center
encouraging result for us.

00:15:26.637 --> 00:15:27.818 align:center
Even if it just was one,

00:15:28.259 --> 00:15:30.361 align:center
it just followed the same pathway

00:15:30.521 --> 00:15:32.683 align:center
and way in the human as

00:15:32.703 --> 00:15:34.285 align:center
we've seen from the preclinical studies.

00:15:34.785 --> 00:15:35.806 align:center
Very encouraging indeed.

00:15:35.846 --> 00:15:37.268 align:center
And that has, of course, helped

00:15:37.348 --> 00:15:39.410 align:center
us now when we have put

00:15:39.510 --> 00:15:42.753 align:center
up the preliminary phase two study

00:15:42.794 --> 00:15:43.154 align:center
program.

00:15:43.194 --> 00:15:43.975 align:center
But I will come back to

00:15:44.015 --> 00:15:44.816 align:center
that a little later.

00:15:45.977 --> 00:15:47.659 align:center
And so, yeah.

00:15:48.517 --> 00:15:50.498 align:center
Talking about that, I think we

00:15:50.538 --> 00:15:51.458 align:center
go on to the next one

00:15:51.538 --> 00:15:52.838 align:center
and I just talk about that.

00:15:53.378 --> 00:15:54.519 align:center
What will we do in phase

00:15:54.559 --> 00:15:55.199 align:center
two studies?

00:15:55.259 --> 00:15:58.059 align:center
Yeah, we have did a extremely

00:15:58.079 --> 00:16:02.701 align:center
due diligent investigation on this, given

00:16:03.001 --> 00:16:04.821 align:center
the results we had in preclinic

00:16:04.841 --> 00:16:06.482 align:center
and encouraging results we had in

00:16:06.602 --> 00:16:09.202 align:center
phase one study together with our

00:16:09.242 --> 00:16:11.103 align:center
medical experts and other

00:16:13.423 --> 00:16:16.487 align:center
experts in the field and we're

00:16:16.527 --> 00:16:19.430 align:center
homing in here on sickness situations

00:16:19.790 --> 00:16:20.851 align:center
if we relate to the first

00:16:21.071 --> 00:16:22.813 align:center
slice that you look at and

00:16:22.833 --> 00:16:25.336 align:center
the ten biggest here we have

00:16:25.918 --> 00:16:27.319 align:center
Some of them may be more

00:16:27.359 --> 00:16:30.002 align:center
to the point indications and of

00:16:30.042 --> 00:16:31.383 align:center
this in case you can see

00:16:32.024 --> 00:16:34.966 align:center
kidney, you could see pulmonary, I

00:16:35.006 --> 00:16:36.268 align:center
mean from the lungs and so

00:16:36.328 --> 00:16:36.568 align:center
forth.

00:16:37.108 --> 00:16:39.871 align:center
Different situations that emanates from what

00:16:39.891 --> 00:16:41.152 align:center
you've seen from these top ten

00:16:41.953 --> 00:16:44.075 align:center
few slides before this one.

00:16:44.835 --> 00:16:46.476 align:center
And this, of course, have to

00:16:46.496 --> 00:16:48.698 align:center
go through regulatory authorities before we

00:16:48.738 --> 00:16:50.399 align:center
can see what is doable or

00:16:50.439 --> 00:16:53.501 align:center
not and present our study protocols

00:16:53.541 --> 00:16:54.281 align:center
that we have then

00:16:57.303 --> 00:16:58.384 align:center
produced as

00:17:00.225 --> 00:17:01.927 align:center
as a study protocol for this

00:17:01.947 --> 00:17:02.808 align:center
phase two studies.

00:17:03.469 --> 00:17:04.390 align:center
And it remains to be seen,

00:17:04.430 --> 00:17:06.753 align:center
but all these ones are in

00:17:06.793 --> 00:17:09.276 align:center
the field of leading to sepsis

00:17:10.017 --> 00:17:12.359 align:center
or it could happen during sepsis.

00:17:12.820 --> 00:17:14.462 align:center
So they're all relevant.

00:17:14.922 --> 00:17:15.323 align:center
And again,

00:17:15.963 --> 00:17:17.303 align:center
I ask you to think about

00:17:17.343 --> 00:17:18.664 align:center
this top ten that we just

00:17:19.004 --> 00:17:21.204 align:center
spoke about a few slides about.

00:17:21.884 --> 00:17:23.124 align:center
Also in this one, just for

00:17:23.144 --> 00:17:24.825 align:center
a regulatory standpoint of things when

00:17:24.885 --> 00:17:26.385 align:center
it comes to the authorities is

00:17:26.425 --> 00:17:30.146 align:center
that there are both orphan indications

00:17:30.186 --> 00:17:31.746 align:center
here as regular indications.

00:17:32.306 --> 00:17:33.286 align:center
And what we are looking here

00:17:33.366 --> 00:17:35.566 align:center
is that have a speedy as

00:17:35.626 --> 00:17:40.207 align:center
possible forward moving study to save

00:17:40.247 --> 00:17:40.967 align:center
time and money.

00:17:41.207 --> 00:17:42.328 align:center
And we, of course, want to

00:17:42.388 --> 00:17:43.508 align:center
reach the market as soon as

00:17:43.588 --> 00:17:43.988 align:center
possible.

00:17:44.768 --> 00:17:46.170 align:center
And that will also be a

00:17:46.250 --> 00:17:48.492 align:center
very important part when you judge

00:17:48.832 --> 00:17:50.173 align:center
what to choose and what to

00:17:50.213 --> 00:17:51.955 align:center
go forward with in phase two

00:17:51.995 --> 00:17:53.316 align:center
studies next to come.

00:17:54.557 --> 00:17:56.479 align:center
So with that said, coming back

00:17:56.599 --> 00:17:58.881 align:center
to the industry, where are we?

00:18:00.018 --> 00:18:00.798 align:center
Do we have big sales?

00:18:00.818 --> 00:18:01.978 align:center
Yes, we have enormous sales.

00:18:02.519 --> 00:18:03.799 align:center
And not to us, but in

00:18:03.819 --> 00:18:06.319 align:center
this field of drugs used in

00:18:06.339 --> 00:18:07.039 align:center
sepsis.

00:18:07.459 --> 00:18:08.700 align:center
But if we start looking at

00:18:08.760 --> 00:18:10.300 align:center
the left side, you see here

00:18:10.340 --> 00:18:11.960 align:center
the global market for aptamers.

00:18:12.060 --> 00:18:15.361 align:center
And I will say this will

00:18:15.401 --> 00:18:17.761 align:center
be updated soon because it's really

00:18:17.801 --> 00:18:18.442 align:center
increasing.

00:18:18.482 --> 00:18:19.702 align:center
And as I said, aptamers are

00:18:19.742 --> 00:18:21.082 align:center
part of the oligo industry.

00:18:21.262 --> 00:18:23.082 align:center
And this is very important to

00:18:23.122 --> 00:18:25.603 align:center
remember that this is really booming

00:18:25.683 --> 00:18:26.263 align:center
at the moment.

00:18:27.470 --> 00:18:29.071 align:center
Anyway, if you look at the

00:18:29.371 --> 00:18:31.471 align:center
right side, these are one of

00:18:31.491 --> 00:18:33.592 align:center
the benchmark drugs that we tested

00:18:33.632 --> 00:18:33.892 align:center
against.

00:18:34.733 --> 00:18:37.313 align:center
Heparin, Voraxepar and Rivoraxaban, very well

00:18:37.353 --> 00:18:37.593 align:center
known.

00:18:37.653 --> 00:18:39.894 align:center
And please note this, the mid

00:18:40.034 --> 00:18:40.995 align:center
one, Voraxepar.

00:18:41.395 --> 00:18:43.275 align:center
We did a benchmark testing against

00:18:43.295 --> 00:18:44.176 align:center
that and you can see how

00:18:44.236 --> 00:18:45.876 align:center
much money it generates per year.

00:18:45.916 --> 00:18:48.237 align:center
And of course, you know, gaining

00:18:48.277 --> 00:18:49.537 align:center
interest to take this all the

00:18:49.557 --> 00:18:50.558 align:center
way to market, you need to

00:18:50.618 --> 00:18:51.218 align:center
have some kind of

00:18:51.923 --> 00:18:54.325 align:center
market potential and there definitely is

00:18:54.425 --> 00:18:55.485 align:center
but coming back to Vorex and

00:18:55.505 --> 00:18:57.447 align:center
PAR we did benchmarking and we

00:18:57.487 --> 00:18:58.748 align:center
could see that our drug was

00:18:59.088 --> 00:19:01.950 align:center
absolutely superior to this one in

00:19:01.990 --> 00:19:03.391 align:center
those tests we did and also

00:19:03.691 --> 00:19:05.212 align:center
without the side effects because Vorex

00:19:05.232 --> 00:19:06.653 align:center
and PAR have side effects but

00:19:06.833 --> 00:19:07.814 align:center
this is something we will not

00:19:07.854 --> 00:19:11.796 align:center
talk about today but please remember

00:19:12.097 --> 00:19:14.558 align:center
that so far we have not

00:19:14.598 --> 00:19:16.079 align:center
seen any side effects without the

00:19:16.159 --> 00:19:19.021 align:center
one so that's a good start

00:19:19.061 --> 00:19:20.162 align:center
for the next step we want

00:19:20.182 --> 00:19:21.403 align:center
to take with phase two studies

00:19:22.440 --> 00:19:25.322 align:center
Anyway, so I just talked about

00:19:25.382 --> 00:19:26.362 align:center
phase two, and you see that

00:19:26.422 --> 00:19:27.122 align:center
on the far right.

00:19:27.162 --> 00:19:28.463 align:center
But this is a little overview

00:19:28.483 --> 00:19:29.364 align:center
of what we have done and

00:19:29.404 --> 00:19:30.204 align:center
where we are going.

00:19:30.464 --> 00:19:32.025 align:center
I just talked about preclinical before.

00:19:32.045 --> 00:19:35.287 align:center
A lot of preclinical studies we

00:19:35.327 --> 00:19:36.627 align:center
have done, and it resulted in

00:19:36.667 --> 00:19:38.989 align:center
a few very strong publications and

00:19:39.049 --> 00:19:40.829 align:center
collaborations around the world.

00:19:41.330 --> 00:19:42.871 align:center
We've done the phase one with

00:19:42.951 --> 00:19:45.332 align:center
that interesting results that we didn't

00:19:45.392 --> 00:19:45.992 align:center
plan, of course.

00:19:46.452 --> 00:19:47.613 align:center
And now we have started planning

00:19:48.193 --> 00:19:49.934 align:center
to take ourselves to the US.

00:19:50.214 --> 00:19:50.975 align:center
And why are we doing that?

00:19:51.755 --> 00:19:53.356 align:center
because we see there an opportunity

00:19:53.396 --> 00:19:55.598 align:center
to be valued as we would

00:19:55.858 --> 00:19:57.980 align:center
love to be and also tap

00:19:58.400 --> 00:20:00.121 align:center
into the bio industry there the

00:20:00.161 --> 00:20:03.163 align:center
regulatory industry and the big need

00:20:03.824 --> 00:20:05.385 align:center
for new remedies

00:20:06.100 --> 00:20:07.301 align:center
And the US is right now

00:20:07.341 --> 00:20:09.382 align:center
flagging up quite a lot for

00:20:09.442 --> 00:20:10.723 align:center
doing something good in this way.

00:20:10.843 --> 00:20:12.024 align:center
And one of these things or

00:20:12.044 --> 00:20:13.065 align:center
two of these things you see

00:20:13.125 --> 00:20:15.647 align:center
below in the smaller mid rings

00:20:15.687 --> 00:20:19.189 align:center
there, FDI pre-check and CNPV pilot

00:20:19.209 --> 00:20:19.630 align:center
program.

00:20:19.910 --> 00:20:20.650 align:center
I will not talk so much

00:20:20.710 --> 00:20:21.271 align:center
about them here.

00:20:21.411 --> 00:20:22.692 align:center
I will have a slide later

00:20:22.752 --> 00:20:23.252 align:center
about those.

00:20:23.933 --> 00:20:25.554 align:center
But these are incentives to actually

00:20:25.594 --> 00:20:27.895 align:center
accelerate development in the US and

00:20:28.436 --> 00:20:30.497 align:center
speed up drugs to the market

00:20:30.577 --> 00:20:31.198 align:center
and so forth.

00:20:32.258 --> 00:20:33.599 align:center
So we just also did an

00:20:33.679 --> 00:20:34.599 align:center
IP expansion.

00:20:34.639 --> 00:20:35.419 align:center
I will come back to that

00:20:35.479 --> 00:20:36.040 align:center
soon as well.

00:20:36.320 --> 00:20:37.580 align:center
But right now, the most important

00:20:37.600 --> 00:20:39.541 align:center
is that we're building a case

00:20:40.121 --> 00:20:41.801 align:center
to comply with US needs to

00:20:41.841 --> 00:20:44.182 align:center
make a introduction to the US

00:20:44.202 --> 00:20:45.783 align:center
stock market without the ham and

00:20:45.863 --> 00:20:46.243 align:center
by that.

00:20:46.931 --> 00:20:49.454 align:center
hopefully be valued, as I just

00:20:49.514 --> 00:20:51.516 align:center
mentioned at the beginning, in a

00:20:51.576 --> 00:20:52.697 align:center
way so we can raise the

00:20:52.717 --> 00:20:54.479 align:center
capital to run the phase two

00:20:54.499 --> 00:20:56.301 align:center
studies and also expand our program,

00:20:56.321 --> 00:20:57.282 align:center
because we have a lot of

00:20:57.362 --> 00:21:00.386 align:center
ideas and fantastic indications in many

00:21:00.466 --> 00:21:01.827 align:center
other ways that I can't disclose

00:21:01.847 --> 00:21:02.148 align:center
today.

00:21:02.248 --> 00:21:03.729 align:center
But that's something we would like

00:21:03.769 --> 00:21:04.911 align:center
to expand on and build a

00:21:04.951 --> 00:21:05.772 align:center
company from there.

00:21:06.913 --> 00:21:08.475 align:center
So with that said,

00:21:10.211 --> 00:21:11.472 align:center
short i will not go through

00:21:11.512 --> 00:21:12.993 align:center
everything i just mentioned is the

00:21:13.113 --> 00:21:16.535 align:center
different fda in sentiments again they

00:21:16.595 --> 00:21:18.616 align:center
are to speed up things to

00:21:18.656 --> 00:21:20.557 align:center
make shorter time with the regulators

00:21:20.577 --> 00:21:22.498 align:center
you can get into your testing

00:21:22.558 --> 00:21:23.879 align:center
and also go to the market

00:21:23.919 --> 00:21:26.320 align:center
faster and the one to the

00:21:26.641 --> 00:21:29.362 align:center
left is the fda pre-check program

00:21:29.382 --> 00:21:31.664 align:center
it's about manufacturing u.s want to

00:21:31.764 --> 00:21:35.026 align:center
secure manufacturing in the country and

00:21:35.586 --> 00:21:37.027 align:center
as such they have now uh

00:21:37.927 --> 00:21:41.190 align:center
release this possibility to apply for

00:21:41.210 --> 00:21:44.994 align:center
a speedier treatment of your manufacturing.

00:21:45.434 --> 00:21:47.656 align:center
So this is two strong things

00:21:48.837 --> 00:21:51.980 align:center
to watch for Abtaham because with

00:21:52.020 --> 00:21:53.202 align:center
our incitement to going to the

00:21:53.342 --> 00:21:53.502 align:center
US,

00:21:54.608 --> 00:21:56.210 align:center
There have been a first round

00:21:56.490 --> 00:21:59.032 align:center
of announcements who got these pre-checks.

00:21:59.393 --> 00:22:00.554 align:center
We were not in it, but

00:22:00.774 --> 00:22:02.135 align:center
it also will continue.

00:22:02.155 --> 00:22:03.196 align:center
So it's not stopped there.

00:22:03.236 --> 00:22:04.878 align:center
So we are still hopeful that

00:22:04.978 --> 00:22:07.320 align:center
it will happen something in front

00:22:07.360 --> 00:22:07.580 align:center
of us.

00:22:07.640 --> 00:22:09.142 align:center
But of course, we will report

00:22:09.202 --> 00:22:11.684 align:center
that when we know where we

00:22:11.724 --> 00:22:12.645 align:center
are with these programs.

00:22:14.531 --> 00:22:16.434 align:center
And I mentioned the patent, and

00:22:16.614 --> 00:22:19.498 align:center
on the side of it is

00:22:19.638 --> 00:22:22.341 align:center
my co-founder, Dr. Jadlina, who is

00:22:22.382 --> 00:22:24.665 align:center
the lead of this program and

00:22:24.705 --> 00:22:26.347 align:center
the development of APTA One and

00:22:26.687 --> 00:22:29.811 align:center
brought it forward today, has during...

00:22:30.532 --> 00:22:32.553 align:center
quite some time now investigated and

00:22:32.653 --> 00:22:34.194 align:center
look at the mechanism look at

00:22:34.274 --> 00:22:36.655 align:center
our results did a lot of

00:22:36.695 --> 00:22:38.956 align:center
partnering and not part of collaboration

00:22:38.996 --> 00:22:41.837 align:center
studies and have found that we

00:22:41.877 --> 00:22:43.978 align:center
could see an even broader application

00:22:44.018 --> 00:22:45.759 align:center
for that one which we now

00:22:46.199 --> 00:22:47.780 align:center
want to secure the protection of

00:22:47.840 --> 00:22:49.721 align:center
hence we did a us provisional

00:22:49.761 --> 00:22:54.023 align:center
patent application earlier this autumn and

00:22:54.323 --> 00:22:56.885 align:center
to secure some other indications and

00:22:56.985 --> 00:22:57.525 align:center
one of these

00:22:58.005 --> 00:22:58.886 align:center
few of these you see here,

00:22:58.946 --> 00:23:01.748 align:center
neurodegenerative diseases like Alzheimer's,

00:23:01.768 --> 00:23:02.248 align:center
for example,

00:23:02.288 --> 00:23:06.491 align:center
viral infections, cancer, fibrotic diseases.

00:23:06.851 --> 00:23:09.052 align:center
So there's a lot of where

00:23:09.093 --> 00:23:10.473 align:center
we can see that the mechanism

00:23:10.513 --> 00:23:12.295 align:center
and the target of APTA-One would

00:23:12.335 --> 00:23:12.575 align:center
have a

00:23:12.964 --> 00:23:14.805 align:center
great and big impact on these

00:23:14.945 --> 00:23:17.507 align:center
different disease indications.

00:23:17.527 --> 00:23:19.628 align:center
So this is broadening the previous

00:23:19.688 --> 00:23:22.409 align:center
patent in patent family of Aptahem,

00:23:22.429 --> 00:23:24.611 align:center
patent family two, where we have

00:23:24.631 --> 00:23:26.592 align:center
then a use patent and indications

00:23:26.692 --> 00:23:27.172 align:center
of that one.

00:23:27.232 --> 00:23:28.893 align:center
So it's just to secure a

00:23:29.073 --> 00:23:31.635 align:center
few more indications, which is really

00:23:31.695 --> 00:23:33.316 align:center
interesting and that we are working

00:23:33.356 --> 00:23:35.077 align:center
hard on moving forward on.

00:23:35.297 --> 00:23:36.798 align:center
So this will be very exciting

00:23:37.138 --> 00:23:37.418 align:center
to come.

00:23:37.858 --> 00:23:38.499 align:center
We do think so.

00:23:40.019 --> 00:23:41.660 align:center
And yeah, we're talking about the

00:23:41.740 --> 00:23:41.821 align:center
US.

00:23:42.979 --> 00:23:44.860 align:center
And just to see where could

00:23:44.920 --> 00:23:47.522 align:center
we be, given what we are

00:23:47.562 --> 00:23:48.643 align:center
doing and what we are heading

00:23:48.703 --> 00:23:50.224 align:center
for, Sepsis and the candidate we

00:23:50.264 --> 00:23:50.464 align:center
have.

00:23:50.905 --> 00:23:53.566 align:center
Here's a few examples of useless

00:23:53.626 --> 00:23:54.367 align:center
companies.

00:23:54.567 --> 00:23:56.248 align:center
And I think the interesting part

00:23:56.268 --> 00:23:57.649 align:center
is actually what you see on

00:23:57.689 --> 00:24:00.451 align:center
the far right side, their market

00:24:00.491 --> 00:24:00.751 align:center
caps.

00:24:01.352 --> 00:24:02.313 align:center
And these are, of course, market

00:24:02.353 --> 00:24:03.774 align:center
caps that we are not today.

00:24:03.974 --> 00:24:05.695 align:center
So, again, I come back to

00:24:05.735 --> 00:24:06.395 align:center
what I said before.

00:24:06.415 --> 00:24:07.256 align:center
Yes, we would say so.

00:24:08.917 --> 00:24:09.537 align:center
We think so.

00:24:09.977 --> 00:24:11.618 align:center
It remains to be seen, of

00:24:11.678 --> 00:24:13.439 align:center
course, but we are working hard

00:24:13.499 --> 00:24:16.520 align:center
on creating a good and compliant

00:24:18.821 --> 00:24:21.362 align:center
bag of company goodies to bring

00:24:21.422 --> 00:24:23.943 align:center
forward to US investors and do

00:24:24.003 --> 00:24:27.765 align:center
that step into the US market

00:24:28.205 --> 00:24:30.146 align:center
and being listed in the US.

00:24:30.846 --> 00:24:31.627 align:center
So that's what we have to

00:24:31.647 --> 00:24:32.247 align:center
look for.

00:24:33.848 --> 00:24:34.830 align:center
And a little about the team.

00:24:35.452 --> 00:24:36.874 align:center
This is the management and board.

00:24:37.676 --> 00:24:39.820 align:center
I just mentioned Dr. Luisa Gedlina

00:24:39.840 --> 00:24:40.061 align:center
there.

00:24:40.542 --> 00:24:42.706 align:center
She has been key and instrumental

00:24:42.847 --> 00:24:43.969 align:center
in bringing us forward when it

00:24:44.009 --> 00:24:44.851 align:center
comes to technology.

00:24:46.606 --> 00:24:50.088 align:center
Ola here, our financial guy, has

00:24:50.108 --> 00:24:51.369 align:center
been with us since the beginning

00:24:51.409 --> 00:24:51.729 align:center
actually.

00:24:52.309 --> 00:24:55.331 align:center
Panolin, very seasoned and skilled MD,

00:24:55.411 --> 00:24:56.831 align:center
done a lot of things when

00:24:56.871 --> 00:24:58.212 align:center
it comes to clinical studies, been

00:24:58.232 --> 00:25:03.835 align:center
a good collaborator with our CSO,

00:25:04.275 --> 00:25:07.677 align:center
Dr. Jelena, going forward with the

00:25:07.717 --> 00:25:10.898 align:center
synopsis, the planned study package for

00:25:10.958 --> 00:25:11.499 align:center
phase two.

00:25:12.619 --> 00:25:13.979 align:center
and thomas roop below is a

00:25:14.079 --> 00:25:16.440 align:center
world leading expert in oligos in

00:25:16.480 --> 00:25:18.421 align:center
the aptamer world and he's been

00:25:18.681 --> 00:25:20.281 align:center
really a key for us to

00:25:20.421 --> 00:25:21.381 align:center
take us where we are today

00:25:21.421 --> 00:25:22.242 align:center
and we would say we are

00:25:22.362 --> 00:25:24.702 align:center
leading in manufacturing that type of

00:25:24.842 --> 00:25:26.483 align:center
oligos or rna after that we

00:25:26.523 --> 00:25:28.483 align:center
have we also have a board

00:25:28.623 --> 00:25:30.044 align:center
a seasoned board that you can

00:25:30.064 --> 00:25:31.464 align:center
see to the right i'm there

00:25:31.504 --> 00:25:33.784 align:center
right now uh we are of

00:25:33.864 --> 00:25:35.425 align:center
course looking at at um

00:25:36.175 --> 00:25:37.916 align:center
skilled people all the time but

00:25:38.237 --> 00:25:40.518 align:center
we are a small semi-virtual company

00:25:40.558 --> 00:25:41.219 align:center
and we have a lot of

00:25:41.259 --> 00:25:44.121 align:center
collaborations we have consultants that we

00:25:44.141 --> 00:25:45.342 align:center
tap in from time to time

00:25:45.422 --> 00:25:47.383 align:center
so our network is extremely wide

00:25:47.503 --> 00:25:49.204 align:center
and it goes global to tap

00:25:49.264 --> 00:25:52.507 align:center
into uh so so uh looking

00:25:52.567 --> 00:25:54.388 align:center
forward uh it will be really

00:25:54.428 --> 00:25:56.430 align:center
exciting to continue working with these

00:25:56.730 --> 00:25:57.650 align:center
fine individuals

00:25:58.951 --> 00:26:01.554 align:center
And as a final slide, current

00:26:01.574 --> 00:26:03.015 align:center
focus, I've been talking about it

00:26:03.075 --> 00:26:03.915 align:center
a little, but I will give

00:26:03.935 --> 00:26:06.297 align:center
some more information.

00:26:06.357 --> 00:26:08.679 align:center
And right now, talking about financial

00:26:08.719 --> 00:26:10.381 align:center
and that's moving towards the U.S.

00:26:10.441 --> 00:26:13.223 align:center
and the compliance with the U.S.

00:26:13.483 --> 00:26:14.944 align:center
needs that comes to auditing.

00:26:14.984 --> 00:26:16.646 align:center
And we are right now changing

00:26:16.666 --> 00:26:18.067 align:center
our system to what is called

00:26:18.107 --> 00:26:18.788 align:center
the AFRS.

00:26:19.668 --> 00:26:21.270 align:center
And that is an ongoing thing.

00:26:21.310 --> 00:26:22.491 align:center
And we come some distance.

00:26:22.531 --> 00:26:23.071 align:center
We already...

00:26:24.513 --> 00:26:25.716 align:center
Almost there, I would say so.

00:26:26.197 --> 00:26:27.300 align:center
And we're also doing this to

00:26:27.340 --> 00:26:28.162 align:center
prepare our U.S.

00:26:28.242 --> 00:26:30.307 align:center
auditor, which is mandatory to be

00:26:30.528 --> 00:26:31.931 align:center
compliant with the U.S.

00:26:32.192 --> 00:26:32.953 align:center
investor interest.

00:26:36.349 --> 00:26:41.152 align:center
analytic then diligence that will be

00:26:41.172 --> 00:26:43.934 align:center
done on us and operational yes

00:26:44.014 --> 00:26:45.374 align:center
we are on the field working

00:26:45.975 --> 00:26:48.496 align:center
on on partnership and so forth

00:26:48.596 --> 00:26:50.898 align:center
and keeping ourselves visual out there

00:26:51.638 --> 00:26:52.879 align:center
we just came back from by

00:26:52.939 --> 00:26:56.361 align:center
japan intense trip we had a

00:26:56.381 --> 00:26:57.201 align:center
lot of follow-ups

00:26:58.859 --> 00:27:00.841 align:center
Took some good time to deliver

00:27:00.961 --> 00:27:02.102 align:center
the material to them, and we

00:27:02.142 --> 00:27:03.583 align:center
have really nice interest.

00:27:03.983 --> 00:27:04.924 align:center
Something I will need to come

00:27:04.964 --> 00:27:06.065 align:center
back to later, of course, if

00:27:06.185 --> 00:27:08.567 align:center
it turns out to be more

00:27:08.627 --> 00:27:09.327 align:center
hot, so to say.

00:27:10.148 --> 00:27:12.209 align:center
And I'm going from down and

00:27:12.269 --> 00:27:12.770 align:center
up, of course.

00:27:13.110 --> 00:27:14.911 align:center
Communication with prospective US investors.

00:27:14.952 --> 00:27:17.033 align:center
We have an ongoing dialogue or

00:27:17.133 --> 00:27:19.615 align:center
dialogues, we would say, with different

00:27:19.675 --> 00:27:20.196 align:center
investors.

00:27:20.736 --> 00:27:22.097 align:center
They are, of course, dependent on

00:27:22.117 --> 00:27:23.858 align:center
that we deliver on the compliance

00:27:23.938 --> 00:27:25.179 align:center
needs when it comes to the

00:27:25.219 --> 00:27:25.580 align:center
auditing.

00:27:25.600 --> 00:27:26.881 align:center
That's key in this whole thing.

00:27:26.901 --> 00:27:27.821 align:center
This is why we're working so

00:27:27.862 --> 00:27:28.342 align:center
hard with that.

00:27:29.263 --> 00:27:30.263 align:center
And we also have a legal

00:27:30.303 --> 00:27:34.745 align:center
counsel and advisors for going to

00:27:34.765 --> 00:27:35.686 align:center
the US that have done it

00:27:35.726 --> 00:27:39.207 align:center
several times more than just this

00:27:39.247 --> 00:27:41.528 align:center
time and have great experience doing

00:27:41.548 --> 00:27:41.728 align:center
this.

00:27:42.328 --> 00:27:43.549 align:center
So all in all, we are

00:27:43.969 --> 00:27:45.349 align:center
full head focus on the US,

00:27:45.450 --> 00:27:46.410 align:center
but we're also working

00:27:47.116 --> 00:27:50.017 align:center
on our current dialogues and partnership,

00:27:50.977 --> 00:27:53.418 align:center
as well as investors side of

00:27:53.458 --> 00:27:53.718 align:center
things.

00:27:54.458 --> 00:27:56.439 align:center
So we feel very strengthened and

00:27:56.499 --> 00:27:58.920 align:center
we had very good, very good

00:27:59.120 --> 00:28:01.360 align:center
feedback lately, as I just said,

00:28:01.481 --> 00:28:03.021 align:center
and Buy Japan was one of

00:28:03.041 --> 00:28:04.261 align:center
those, and we hope that will

00:28:04.301 --> 00:28:05.562 align:center
continue now and Buy Europe.

00:28:06.202 --> 00:28:06.982 align:center
And I will come back to

00:28:07.022 --> 00:28:09.883 align:center
you guys as we move forward

00:28:09.983 --> 00:28:11.504 align:center
and deliver those milestones we need

00:28:11.524 --> 00:28:13.784 align:center
to deliver on, especially to be

00:28:13.824 --> 00:28:15.205 align:center
compliant to go to the US.

00:28:16.834 --> 00:28:18.515 align:center
So with that, I thank you

00:28:18.555 --> 00:28:19.795 align:center
very much for your attention.

00:28:20.116 --> 00:28:22.857 align:center
And I leave back the floor

00:28:22.937 --> 00:28:25.938 align:center
to Erika for the questions and

00:28:25.978 --> 00:28:26.298 align:center
answers.

00:28:27.098 --> 00:28:27.319 align:center
Yes.

00:28:28.979 --> 00:28:30.920 align:center
And I can see that we

00:28:31.000 --> 00:28:31.400 align:center
have

00:28:34.261 --> 00:28:35.642 align:center
a question coming in.

00:28:35.942 --> 00:28:41.184 align:center
So let's see if I share

00:28:41.484 --> 00:28:45.366 align:center
or I will click on the

00:28:47.785 --> 00:28:48.245 align:center
I can answer.

00:28:48.306 --> 00:28:49.506 align:center
I see it actually from here.

00:28:49.867 --> 00:28:52.168 align:center
Yeah, there you go.

00:28:52.628 --> 00:28:54.430 align:center
Why is the US listing a

00:28:54.630 --> 00:28:57.011 align:center
better alternative than raising capital in

00:28:57.052 --> 00:28:58.613 align:center
Sweden or the EU?

00:29:00.074 --> 00:29:01.995 align:center
Well, we have been around now

00:29:02.075 --> 00:29:05.137 align:center
for more than eleven years and

00:29:06.738 --> 00:29:08.599 align:center
we see that the financial climate

00:29:08.659 --> 00:29:10.381 align:center
for us and also the valuation

00:29:10.421 --> 00:29:12.182 align:center
we have here is not going

00:29:12.202 --> 00:29:13.062 align:center
to do it for us when

00:29:13.122 --> 00:29:13.683 align:center
it comes to

00:29:14.784 --> 00:29:16.245 align:center
the capital need for maker phase

00:29:16.345 --> 00:29:17.946 align:center
two we also see that us

00:29:18.006 --> 00:29:19.547 align:center
is very vibrant right now and

00:29:19.567 --> 00:29:20.828 align:center
want to make a lot of

00:29:20.848 --> 00:29:22.549 align:center
things happening and and by i

00:29:22.790 --> 00:29:25.031 align:center
just explain for you these different

00:29:25.091 --> 00:29:27.433 align:center
programs that have been been announced

00:29:27.473 --> 00:29:29.094 align:center
and that we have been part

00:29:29.134 --> 00:29:31.295 align:center
of applying to um and also

00:29:31.335 --> 00:29:32.696 align:center
we do believe we can reach

00:29:32.756 --> 00:29:35.378 align:center
a better valuation in the u.s

00:29:35.398 --> 00:29:37.339 align:center
and there are a very healthy

00:29:37.400 --> 00:29:39.301 align:center
climate when it comes to investment

00:29:39.361 --> 00:29:42.043 align:center
in the bio area pharma bio

00:29:42.143 --> 00:29:42.383 align:center
area

00:29:42.870 --> 00:29:45.591 align:center
so and we also recently let's

00:29:45.611 --> 00:29:46.332 align:center
say right in the beginning of

00:29:46.372 --> 00:29:48.833 align:center
this year managed to to get

00:29:48.933 --> 00:29:51.934 align:center
those networks and contacts that leads

00:29:52.054 --> 00:29:54.355 align:center
us to to serious investors and

00:29:54.535 --> 00:29:55.816 align:center
and the dialogues we have been

00:29:56.456 --> 00:29:58.037 align:center
talking to them and and so

00:29:58.097 --> 00:29:59.357 align:center
forth so that's where we are

00:29:59.397 --> 00:30:00.498 align:center
today so it's a lot of

00:30:00.538 --> 00:30:04.019 align:center
different things going into big forward-moving

00:30:04.039 --> 00:30:06.200 align:center
uh action from our side i

00:30:06.220 --> 00:30:08.862 align:center
think okay thank you

00:30:11.683 --> 00:30:11.803 align:center
and

00:30:12.414 --> 00:30:13.314 align:center
Next question.

00:30:14.095 --> 00:30:15.415 align:center
Based on your review of the

00:30:15.455 --> 00:30:17.316 align:center
number of deaths caused by sepsis,

00:30:17.556 --> 00:30:19.496 align:center
do you sense an increased awareness

00:30:19.676 --> 00:30:21.857 align:center
of the problem with unsuccessful sepsis?

00:30:23.678 --> 00:30:25.878 align:center
Well, the number of deaths, I

00:30:25.918 --> 00:30:27.819 align:center
mean, this is nothing new for

00:30:27.919 --> 00:30:29.599 align:center
us in the business, of course,

00:30:29.699 --> 00:30:32.260 align:center
and maybe for the common guy

00:30:32.300 --> 00:30:33.401 align:center
on the street, maybe it's not

00:30:33.461 --> 00:30:34.161 align:center
so common.

00:30:36.058 --> 00:30:37.319 align:center
you know, in the knowledge.

00:30:38.419 --> 00:30:39.679 align:center
We see an increase all the

00:30:39.719 --> 00:30:40.039 align:center
time.

00:30:40.380 --> 00:30:41.800 align:center
We see that there comes new

00:30:41.860 --> 00:30:44.601 align:center
candidates in the making, in the

00:30:44.941 --> 00:30:47.402 align:center
process of going towards market for

00:30:47.622 --> 00:30:49.263 align:center
different development paths.

00:30:50.043 --> 00:30:52.764 align:center
And there are new modalities like

00:30:53.104 --> 00:30:55.465 align:center
we have our RNA ectomers that

00:30:55.505 --> 00:30:56.785 align:center
may open up these doors.

00:30:56.905 --> 00:30:59.066 align:center
And we are very confident about

00:30:59.146 --> 00:31:00.226 align:center
our own drug, but there are

00:31:00.266 --> 00:31:02.147 align:center
others out there that see a

00:31:02.187 --> 00:31:03.528 align:center
possibility perhaps to

00:31:05.194 --> 00:31:06.415 align:center
to find some kind of a

00:31:06.475 --> 00:31:08.436 align:center
cure, remedy, whatever you would call

00:31:08.456 --> 00:31:10.477 align:center
it, at least to take down

00:31:10.517 --> 00:31:11.958 align:center
these death tolls that we see

00:31:12.018 --> 00:31:12.598 align:center
from sepsis.

00:31:12.638 --> 00:31:13.859 align:center
And also there's a lot of

00:31:13.919 --> 00:31:16.240 align:center
work with awareness about sepsis.

00:31:17.080 --> 00:31:21.303 align:center
There's forums, there's sentiments, and before

00:31:21.383 --> 00:31:24.184 align:center
it says like the total impossible

00:31:24.264 --> 00:31:25.365 align:center
to deal with this, and there's

00:31:25.405 --> 00:31:26.746 align:center
been so many failures through the

00:31:26.786 --> 00:31:28.887 align:center
years, but with these new modalities,

00:31:29.387 --> 00:31:30.768 align:center
there is good hope to do

00:31:30.828 --> 00:31:31.148 align:center
something.

00:31:31.248 --> 00:31:32.729 align:center
Of course, other things are developing

00:31:32.749 --> 00:31:33.429 align:center
during this time,

00:31:35.113 --> 00:31:36.774 align:center
we and other companies focus on

00:31:36.874 --> 00:31:39.817 align:center
finding a remedy for sepsis, that

00:31:39.897 --> 00:31:40.217 align:center
helps.

00:31:40.377 --> 00:31:42.779 align:center
But still, it actually is an

00:31:42.839 --> 00:31:45.641 align:center
increase, the death tolls, what we

00:31:45.661 --> 00:31:46.702 align:center
can see from other numbers.

00:31:46.762 --> 00:31:50.625 align:center
So there's definitely a need for

00:31:50.645 --> 00:31:51.305 align:center
a remedy here.

00:31:51.525 --> 00:31:56.629 align:center
And the awareness among us that

00:31:56.669 --> 00:32:00.152 align:center
develop candidates towards sepsis is

00:32:00.212 --> 00:32:00.712 align:center
increasing.

00:32:00.772 --> 00:32:01.913 align:center
So that's a good thing, I

00:32:01.933 --> 00:32:02.273 align:center
think so.

00:32:03.855 --> 00:32:04.215 align:center
Thank you.

00:32:05.653 --> 00:32:07.956 align:center
Over to the next question.

00:32:09.498 --> 00:32:11.440 align:center
Are there any risks associated with

00:32:11.460 --> 00:32:13.282 align:center
the US listing and how are

00:32:13.322 --> 00:32:15.064 align:center
you working to manage them if

00:32:15.144 --> 00:32:15.725 align:center
they exist?

00:32:17.107 --> 00:32:20.489 align:center
there's always uh risks involved in

00:32:20.549 --> 00:32:21.949 align:center
anything you do until you can

00:32:21.989 --> 00:32:23.250 align:center
conclude and say how did it

00:32:23.330 --> 00:32:25.070 align:center
go uh we try to do

00:32:25.111 --> 00:32:26.711 align:center
risk this as much as possible

00:32:26.731 --> 00:32:27.892 align:center
of course and and with the

00:32:27.952 --> 00:32:29.572 align:center
networks and the people we are

00:32:29.612 --> 00:32:33.134 align:center
now associating ourselves with uh when

00:32:33.174 --> 00:32:34.134 align:center
it comes to the legal side

00:32:34.154 --> 00:32:35.715 align:center
of things and also auditing side

00:32:35.735 --> 00:32:38.356 align:center
of things advisable advisor side of

00:32:38.416 --> 00:32:39.297 align:center
things and also the

00:32:40.277 --> 00:32:42.038 align:center
the the the contact we had

00:32:42.118 --> 00:32:43.820 align:center
and discussion or dialogues we had

00:32:43.920 --> 00:32:46.982 align:center
with potential investors um you know

00:32:48.003 --> 00:32:51.625 align:center
for us it's a possibility but

00:32:51.946 --> 00:32:53.587 align:center
nothing is given until it happens

00:32:53.807 --> 00:32:55.508 align:center
and that could be you know

00:32:55.588 --> 00:32:57.290 align:center
things out of our own control

00:32:57.390 --> 00:32:57.430 align:center
or

00:32:58.110 --> 00:32:59.571 align:center
the ones we would like to

00:32:59.611 --> 00:33:01.333 align:center
work with out of control that

00:33:01.393 --> 00:33:02.614 align:center
makes this not happen.

00:33:03.134 --> 00:33:04.375 align:center
But we do not hope so,

00:33:04.395 --> 00:33:04.756 align:center
of course.

00:33:04.836 --> 00:33:05.977 align:center
And we have a very good

00:33:06.017 --> 00:33:08.819 align:center
pathway right now how to do

00:33:08.859 --> 00:33:09.039 align:center
this.

00:33:09.139 --> 00:33:11.121 align:center
And if everything holds up, it

00:33:11.301 --> 00:33:13.583 align:center
should hopefully pan out as we

00:33:14.043 --> 00:33:14.464 align:center
plan to do.

00:33:14.484 --> 00:33:16.405 align:center
But this is something that I

00:33:16.465 --> 00:33:18.787 align:center
will tell the market wherever we

00:33:18.807 --> 00:33:20.088 align:center
take this milestone steps, as I

00:33:20.129 --> 00:33:22.490 align:center
mentioned before, and tell where we

00:33:22.531 --> 00:33:23.912 align:center
are going and how we're doing

00:33:23.952 --> 00:33:24.192 align:center
with that.

00:33:25.580 --> 00:33:26.521 align:center
Okay, thank you.

00:33:26.561 --> 00:33:29.523 align:center
And here's another question on the

00:33:29.583 --> 00:33:30.323 align:center
same topic.

00:33:30.923 --> 00:33:32.144 align:center
How will you manage to be

00:33:32.184 --> 00:33:33.545 align:center
listed on U.S.

00:33:33.685 --> 00:33:34.506 align:center
stock exchange?

00:33:35.506 --> 00:33:37.868 align:center
Well, this is something that we

00:33:37.908 --> 00:33:39.049 align:center
are working on, of course, but

00:33:40.690 --> 00:33:42.271 align:center
with our advisors and the legals

00:33:42.331 --> 00:33:43.512 align:center
that we are working with right

00:33:43.592 --> 00:33:45.713 align:center
now, which have an advanced experience

00:33:45.753 --> 00:33:48.014 align:center
in doing this, that is something

00:33:48.034 --> 00:33:48.995 align:center
we have to come back to

00:33:49.115 --> 00:33:50.116 align:center
how we will do it and

00:33:50.196 --> 00:33:50.896 align:center
what we will do it.

00:33:50.936 --> 00:33:52.417 align:center
But they've done it several times

00:33:52.477 --> 00:33:54.118 align:center
with companies from Europe and especially

00:33:54.138 --> 00:33:54.999 align:center
Scandinavia as well.

00:33:56.973 --> 00:34:00.936 align:center
So the small details will pan

00:34:01.096 --> 00:34:02.977 align:center
out when we go forward and

00:34:03.017 --> 00:34:05.579 align:center
we tap off these milestones I've

00:34:05.599 --> 00:34:06.500 align:center
been mentioning before.

00:34:06.580 --> 00:34:07.621 align:center
So that's all I can say

00:34:07.661 --> 00:34:07.981 align:center
right now.

00:34:10.283 --> 00:34:10.863 align:center
Thank you.

00:34:11.083 --> 00:34:12.404 align:center
And the next question.

00:34:14.166 --> 00:34:15.887 align:center
How do you view the FDA's

00:34:15.967 --> 00:34:20.030 align:center
role in supporting new RNA-based therapies

00:34:20.490 --> 00:34:22.151 align:center
compared to the European authorities?

00:34:22.592 --> 00:34:24.193 align:center
Is the FDA more open to

00:34:24.253 --> 00:34:25.434 align:center
such drug candidates?

00:34:26.769 --> 00:34:28.390 align:center
Well, I don't know really how

00:34:28.430 --> 00:34:29.770 align:center
to answer that question because we

00:34:29.810 --> 00:34:31.231 align:center
have only worked with the European

00:34:31.611 --> 00:34:34.712 align:center
Regulatories and they are very understandable

00:34:34.792 --> 00:34:40.575 align:center
and understands this field of modalities.

00:34:41.055 --> 00:34:43.596 align:center
And FDA, we haven't weathered yet.

00:34:44.176 --> 00:34:47.057 align:center
We just see that there is

00:34:47.537 --> 00:34:48.918 align:center
something happening in the US and

00:34:49.218 --> 00:34:50.419 align:center
there is an openness for this

00:34:50.459 --> 00:34:51.439 align:center
kind of modalities.

00:34:52.119 --> 00:34:53.620 align:center
And before we actually knock on

00:34:53.640 --> 00:34:55.381 align:center
the FDA door, it's too early

00:34:55.421 --> 00:34:56.361 align:center
to say where they are.

00:34:57.722 --> 00:34:59.143 align:center
concerning this because there's so many

00:34:59.163 --> 00:35:00.604 align:center
other factors playing a role of

00:35:01.525 --> 00:35:03.506 align:center
actually introducing something or getting

00:35:03.546 --> 00:35:03.826 align:center
something

00:35:03.866 --> 00:35:05.948 align:center
approved for clinical studies in the

00:35:06.088 --> 00:35:06.408 align:center
US.

00:35:07.009 --> 00:35:08.650 align:center
Hence, what I've just showed before

00:35:08.690 --> 00:35:11.272 align:center
the authorities programs that they have

00:35:11.512 --> 00:35:13.253 align:center
and put out for people to

00:35:13.273 --> 00:35:13.613 align:center
apply.

00:35:13.633 --> 00:35:15.615 align:center
So there is a go in

00:35:15.635 --> 00:35:17.957 align:center
the US side and that might

00:35:17.977 --> 00:35:21.239 align:center
just open up for a wider

00:35:21.319 --> 00:35:22.660 align:center
and understandable way.

00:35:22.720 --> 00:35:23.981 align:center
But in Europe, we have very

00:35:24.021 --> 00:35:24.862 align:center
good regulatory

00:35:27.295 --> 00:35:28.836 align:center
treatment and understanding for the

00:35:28.856 --> 00:35:29.356 align:center
authorities,

00:35:29.416 --> 00:35:30.817 align:center
there was no issues actually.

00:35:31.837 --> 00:35:33.477 align:center
So, too early to say too

00:35:33.498 --> 00:35:34.018 align:center
much about this.

00:35:37.339 --> 00:35:38.179 align:center
Next question.

00:35:39.159 --> 00:35:40.500 align:center
You have applied to both the

00:35:40.800 --> 00:35:43.421 align:center
FDA's PreCheck and CNPV programs.

00:35:44.681 --> 00:35:47.042 align:center
Are they interdependent and what could

00:35:47.082 --> 00:35:49.683 align:center
these initiatives specifically mean for a

00:35:49.763 --> 00:35:52.104 align:center
faster and more efficient development of

00:35:52.204 --> 00:35:52.644 align:center
APTA-One?

00:35:53.757 --> 00:35:55.978 align:center
Well, I spoke about that in

00:35:55.998 --> 00:35:58.358 align:center
my presentation, and it's the FDA

00:35:58.398 --> 00:35:59.838 align:center
that have given this out, and

00:35:59.858 --> 00:36:03.759 align:center
I think the divider between those

00:36:03.799 --> 00:36:05.620 align:center
programs, one is to get a

00:36:05.780 --> 00:36:08.561 align:center
faster regulatory approval, which otherwise

00:36:08.581 --> 00:36:08.721 align:center
could

00:36:08.761 --> 00:36:09.741 align:center
take up to a year or

00:36:09.821 --> 00:36:10.021 align:center
more.

00:36:10.081 --> 00:36:11.341 align:center
Sometimes they want to shorten that

00:36:11.381 --> 00:36:12.422 align:center
time, so you get out and

00:36:12.462 --> 00:36:13.082 align:center
do your study.

00:36:13.642 --> 00:36:15.742 align:center
What that means in terms of

00:36:15.762 --> 00:36:17.503 align:center
easier approval or more

00:36:20.002 --> 00:36:22.085 align:center
less less uh diligent view on

00:36:22.125 --> 00:36:23.967 align:center
things i don't know uh at

00:36:23.987 --> 00:36:25.328 align:center
this point and the other one

00:36:25.428 --> 00:36:26.890 align:center
is about the manufacturing and i

00:36:26.950 --> 00:36:28.452 align:center
mentioned that as well that the

00:36:28.512 --> 00:36:30.674 align:center
manufacturing they want to secure manufacturing

00:36:31.375 --> 00:36:32.937 align:center
in the us to secure the

00:36:32.977 --> 00:36:35.760 align:center
supply of drugs for their u.s

00:36:35.800 --> 00:36:37.862 align:center
citizens so so these are the

00:36:37.882 --> 00:36:38.022 align:center
two

00:36:38.703 --> 00:36:40.503 align:center
differences between those programs.

00:36:41.364 --> 00:36:43.384 align:center
Yes, faster is one, securing is

00:36:43.444 --> 00:36:43.744 align:center
another.

00:36:44.164 --> 00:36:46.425 align:center
So faster through, see, does it

00:36:46.445 --> 00:36:47.585 align:center
bear to the market?

00:36:47.885 --> 00:36:49.366 align:center
And also, can we manufacture a

00:36:49.406 --> 00:36:52.546 align:center
secure drug in our own country?

00:36:52.766 --> 00:36:54.007 align:center
So that's what it's all about.

00:36:55.927 --> 00:36:56.427 align:center
Thank you.

00:36:59.748 --> 00:37:00.848 align:center
Here's another question.

00:37:01.409 --> 00:37:03.009 align:center
What are you doing to drum

00:37:03.089 --> 00:37:05.290 align:center
up the tension about Aptawan among

00:37:05.330 --> 00:37:06.950 align:center
potentially interested companies?

00:37:07.973 --> 00:37:09.254 align:center
Well, this is one way of

00:37:09.314 --> 00:37:10.414 align:center
doing it, of course, when we

00:37:10.434 --> 00:37:11.114 align:center
share this later.

00:37:12.415 --> 00:37:13.535 align:center
We are out on the field

00:37:14.095 --> 00:37:16.957 align:center
and choose wisely the events we

00:37:16.997 --> 00:37:17.677 align:center
are going to.

00:37:19.237 --> 00:37:21.658 align:center
We know that Asia and Japan

00:37:21.678 --> 00:37:23.279 align:center
in particular are very interested in

00:37:23.319 --> 00:37:24.079 align:center
these modalities.

00:37:24.199 --> 00:37:25.500 align:center
Hence, we go to buy Japan

00:37:25.540 --> 00:37:27.881 align:center
and meet with companies there.

00:37:29.081 --> 00:37:30.022 align:center
And now we go to buy

00:37:30.122 --> 00:37:31.202 align:center
Europe, which is one of the

00:37:31.302 --> 00:37:32.403 align:center
bigger events in the world.

00:37:32.523 --> 00:37:34.483 align:center
And next year, we are looking

00:37:34.523 --> 00:37:35.784 align:center
towards to go to JP Morgan.

00:37:36.710 --> 00:37:38.410 align:center
the us of the year so

00:37:38.851 --> 00:37:41.011 align:center
we try to spread into when

00:37:41.071 --> 00:37:43.011 align:center
it comes to partnering and investments

00:37:43.532 --> 00:37:47.592 align:center
or investor events to to reach

00:37:47.672 --> 00:37:49.433 align:center
out there personally of course then

00:37:49.813 --> 00:37:53.154 align:center
we have our feeds on on

00:37:53.414 --> 00:37:55.774 align:center
instagram and uh not instagram but

00:37:55.814 --> 00:37:57.915 align:center
linkedin and facebook and so forth

00:37:58.095 --> 00:37:58.615 align:center
and and

00:37:59.512 --> 00:38:02.174 align:center
We go to different network situations,

00:38:02.634 --> 00:38:04.816 align:center
parties and so forth, where there

00:38:04.836 --> 00:38:08.518 align:center
is a good mix of investors

00:38:08.638 --> 00:38:10.559 align:center
and potential partners, of course.

00:38:10.599 --> 00:38:13.401 align:center
So yeah, we try to be

00:38:13.461 --> 00:38:15.082 align:center
out there and move because you

00:38:15.102 --> 00:38:15.923 align:center
have to be seen to be

00:38:15.963 --> 00:38:16.123 align:center
known.

00:38:19.359 --> 00:38:20.200 align:center
Next question.

00:38:21.561 --> 00:38:23.784 align:center
What type of partnership, big pharma,

00:38:23.864 --> 00:38:26.987 align:center
academic institutions, other biotech is most

00:38:27.047 --> 00:38:28.308 align:center
attractive to you right now?

00:38:28.869 --> 00:38:29.850 align:center
All or do you have a

00:38:29.910 --> 00:38:30.570 align:center
certain focus?

00:38:32.092 --> 00:38:34.114 align:center
Well, we have said for a

00:38:34.134 --> 00:38:36.436 align:center
long time that the partnership would

00:38:36.576 --> 00:38:39.399 align:center
most be most necessary for us

00:38:39.940 --> 00:38:42.562 align:center
to bring this lovely candidate to

00:38:42.602 --> 00:38:43.103 align:center
the market.

00:38:43.677 --> 00:38:44.497 align:center
I mean, we don't have the

00:38:44.517 --> 00:38:46.198 align:center
personnel, we don't have an experience

00:38:46.238 --> 00:38:47.518 align:center
to do the later stages of

00:38:47.999 --> 00:38:50.240 align:center
clinical development and market approvals and

00:38:50.260 --> 00:38:50.680 align:center
so forth.

00:38:50.700 --> 00:38:53.581 align:center
So a partnership that's most truly

00:38:53.601 --> 00:38:54.881 align:center
a big pharma, but it could

00:38:54.981 --> 00:38:57.342 align:center
also be a big biotech or

00:38:57.402 --> 00:38:59.043 align:center
whatever that has the means.

00:39:00.005 --> 00:39:02.206 align:center
financially but also knowledge side of

00:39:02.226 --> 00:39:03.966 align:center
things to bring such a candidate

00:39:04.006 --> 00:39:05.606 align:center
through to the market and that's

00:39:05.806 --> 00:39:06.746 align:center
of course what we want to

00:39:06.766 --> 00:39:08.947 align:center
see on the market for the

00:39:08.967 --> 00:39:10.707 align:center
patients that is the most attractive

00:39:11.187 --> 00:39:12.748 align:center
of course we look in academic

00:39:12.808 --> 00:39:16.869 align:center
institutions to to to further develop

00:39:16.929 --> 00:39:18.689 align:center
and understanding our candidate if there's

00:39:18.709 --> 00:39:20.289 align:center
more to understand that's always something

00:39:20.309 --> 00:39:23.170 align:center
to understand of course but

00:39:24.427 --> 00:39:25.788 align:center
To give a short answer from

00:39:25.888 --> 00:39:28.430 align:center
this long answer so far is

00:39:28.490 --> 00:39:30.572 align:center
that we need a strong partnership

00:39:30.712 --> 00:39:31.573 align:center
to bring it all the way

00:39:31.613 --> 00:39:32.773 align:center
to the market and knows what

00:39:32.793 --> 00:39:33.134 align:center
they're doing.

00:39:33.194 --> 00:39:34.595 align:center
It's very costly, but it also

00:39:34.615 --> 00:39:36.777 align:center
needs a lot of knowledge and

00:39:36.817 --> 00:39:37.177 align:center
backup.

00:39:37.457 --> 00:39:38.438 align:center
So that's what we're looking at.

00:39:41.320 --> 00:39:43.021 align:center
And here is the new question.

00:39:44.562 --> 00:39:46.124 align:center
Let's say five years down the

00:39:46.164 --> 00:39:48.946 align:center
road, what is Uptaham's long-term vision?

00:39:50.277 --> 00:39:52.319 align:center
Wow, that's, yeah, yeah.

00:39:52.499 --> 00:39:53.520 align:center
Then you're allowed to dream a

00:39:53.560 --> 00:39:54.180 align:center
little vision.

00:39:55.161 --> 00:39:56.843 align:center
Of course, I would say so

00:39:57.143 --> 00:40:01.827 align:center
that we are close to getting

00:40:01.867 --> 00:40:04.369 align:center
through the last parts of clinical

00:40:05.390 --> 00:40:08.052 align:center
investigation on APTA-I and see the

00:40:08.293 --> 00:40:09.093 align:center
light in the tunnel.

00:40:10.154 --> 00:40:12.396 align:center
We have more pipelines doing on

00:40:12.596 --> 00:40:13.978 align:center
our, we have other candidates that

00:40:14.018 --> 00:40:16.180 align:center
we haven't developed yet with very

00:40:16.200 --> 00:40:16.600 align:center
interesting

00:40:17.682 --> 00:40:19.703 align:center
potential properties that we would like

00:40:19.723 --> 00:40:22.944 align:center
to develop them and look at

00:40:23.064 --> 00:40:24.924 align:center
other indications, of course, when it

00:40:25.004 --> 00:40:27.325 align:center
comes to our fantastic drug candidate,

00:40:27.385 --> 00:40:30.106 align:center
that's our lead candidate, and that

00:40:30.126 --> 00:40:33.267 align:center
we're prosperous and maybe not having

00:40:33.607 --> 00:40:36.888 align:center
one, but more than one collaboration,

00:40:36.948 --> 00:40:40.069 align:center
partnership or license setup or whatever

00:40:40.869 --> 00:40:43.290 align:center
would mean a collab in the

00:40:43.330 --> 00:40:44.950 align:center
sense of working with someone else,

00:40:44.990 --> 00:40:45.831 align:center
bringing it forward.

00:40:47.863 --> 00:40:50.283 align:center
steady flow of new ideas and

00:40:50.343 --> 00:40:54.064 align:center
also maybe expand with other aptamers

00:40:54.104 --> 00:40:55.044 align:center
in front of us.

00:40:55.084 --> 00:40:56.065 align:center
We have learned a lot through

00:40:56.085 --> 00:40:56.485 align:center
this year.

00:40:56.545 --> 00:40:59.245 align:center
So yeah, that's my vision at

00:40:59.285 --> 00:40:59.625 align:center
the moment.

00:41:01.506 --> 00:41:03.086 align:center
Thank you very much, Mikael.

00:41:03.486 --> 00:41:06.147 align:center
And I cannot see that there

00:41:06.247 --> 00:41:08.187 align:center
are any more questions.

00:41:08.807 --> 00:41:13.148 align:center
So if no one has

00:41:15.063 --> 00:41:17.864 align:center
Anything more to ask, Mikael?

00:41:20.024 --> 00:41:22.245 align:center
I would like to say thank

00:41:22.285 --> 00:41:25.325 align:center
you for attending this webinar.

00:41:25.445 --> 00:41:26.546 align:center
As I said in the beginning,

00:41:26.666 --> 00:41:28.446 align:center
we will publish this on our

00:41:28.506 --> 00:41:31.787 align:center
website and social media channels, LinkedIn

00:41:31.847 --> 00:41:34.787 align:center
and Facebook, in a few days,

00:41:35.388 --> 00:41:36.708 align:center
and you are welcome to attend

00:41:36.748 --> 00:41:37.208 align:center
it again.

00:41:37.328 --> 00:41:38.928 align:center
And you are always welcome to

00:41:38.968 --> 00:41:41.349 align:center
contact us via email

00:41:42.356 --> 00:41:46.041 align:center
info at aptahem.com and you find

00:41:46.081 --> 00:41:50.266 align:center
the details on our website aptahem.com

00:41:52.449 --> 00:41:54.251 align:center
so with that i would like

00:41:54.311 --> 00:41:55.633 align:center
to say thank you very much

00:41:56.254 --> 00:41:58.597 align:center
for today thank you everyone